Efficacy and safety of preoperative short-course radiotherapy combined with neoadjuvant chemotherapy in the treatment of locally advanced mid-low rectal cancer
Objective To analyze the clinical efficacy of preoperative short-course radiotherapy combined with neoadjuvant chemotherapy in locally advanced mid-low rectal cancer.Methods Eighty patients with locally advanced mid-low advanced rectal cancer were enrolled and assigned to single group(preoperative neoadjuvant chemotherapy,n=32)and combination group(preoperative short-course radiotherapy+neoadjuvant chemotherapy,n=48)according to different treatment methods.All of them underwent total mesorectal resection after chemoradiotherapy.The two groups were compared for clinical curative effect,serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),CA199]and immune function(CD3+,CD4+,CD8+)before and after chemoradiotherapy;and the incidence of adverse reactions during chemoradiotherapy was recorded.Results The overall remission rate was higher in combination group than in single group(37.50%vs 15.63%,P<0.05).After chemoradiotherapy,the levels of serum CEA,CA125 and CA199 in both groups were decreased,and they were lower in combination group than in single group(P<0.05).After chemoradiotherapy,the levels of CD3+and CD4+in single group and combination group increased,and the level of CD8+decreased(P<0.05),but there was no statistically significant differences in the above indicators between two groups(P>0.05).Additionally,the difference in adverse reactions between two group was trivial(P>0.05),and no grade-IV adverse reactions occurred in either group.Conclusion The combination of preoperative short-course radiotherapy and neoadjuvant chemotherapy is effective for locally advanced mid-low advanced rectal cancer,and beneficial for increasing overall remission rate and lowering the levels of serum tumor markers,with high safety.
short-course radiotherapyneoadjuvant chemotherapylocally advanced mid-low advanced rectal cancer
万方数据
维普
